Abstract
Objective To evaluate and compare the efficacy and safety of liposome doxorubicin and gemcitabine combined with oxaliplatin in the treatment of recurrent platinum-resistant ovarian cancer. Methods From January 1, 2015 to December 31, 2016, 80 patients from Hunan Cancer Hospital with recurrent platinum-resistant ovarian cancer were divided into two groups by using random number table method, 40 cases in each group: group PLD was treated with liposome doxorubicin and group G/O was treated with gemcitabine combined with oxaliplatin. The therapeutic effects of the two groups were evaluated, the expressions of CA125 after treatment were compared and the occurrence of adverse reactions were observed. Results The objective response rate (ORR) and disease control rate (DCR) were respectively 27.5% (11/40) and 35.0% (14/40) in group PLD, and the ORR and DCR were respectively 22.5%(9/40) and 27.5%(11/40) in group G/O, and there was no significant difference between the two groups (χ2=0.27, P=0.61; χ2=0.52, P=0.47). In PLD group and G/O group, the CA125 values of ORR patients were (61.27±28.11)U/ml and (78.29±34.26)U/ml respectively, with no significant difference (t=1.22, P=0.24), the CA125 values of non ORR patients were (530.07±77.15)U/ml and (551.00±78.78)U/ml respectively, with no significant difference (t=1.04, P=0.30). The main adverse reactions in group PLD were hand foot syndrome and myelosuppression. The main adverse reactions in group G/O were gastrointestinal reaction and myelosuppression. The incidence rates of leucocyte reduction (65.0% vs. 92.5%, χ2=9.04, P=0.005), thrombopenia (15.0% vs. 52.5%, χ2=12.58, P<0.001), anemia (15.0% vs. 40.0%, χ2=6.27, P=0.012), gastrointestinal reaction (17.5% vs. 60.0%, χ2=15.22, P<0.001) and neurotoxicity (5.0% vs. 30.0%, χ2=8.66, P=0.006) in group PLD were lower than those in group G/O, with significant differences. Conclusion The efficacy of two chemotherapy regimens is similar in patients with recurrent platinum-resistant ovarian cancer. Liposome doxorubicin has less adverse reactions than gemcitabine combined with oxaliplatin. Key words: Ovarian neoplasms; Treatment outcome; Doxorubicin
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
